Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Genincode Plc LSE:GENI London Ordinary Share GB00BL97B504 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.80 -3.62% 21.30 20.60 22.00 22.10 21.30 22.10 30,011 15:27:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 1.2 -4.1 -8.1 - 20

GENinCode PLC Notice of Results

02/09/2021 7:00am

UK Regulatory (RNS & others)


Genincode (LSE:GENI)
Historical Stock Chart


From May 2021 to May 2022

Click Here for more Genincode Charts.

TIDMGENI

RNS Number : 4285K

GENinCode PLC

02 September 2021

2 September 2021

GENinCode Plc

("GENinCode" or the "Company")

Notice of results

Analyst briefing and investor presentation

GENinCode Plc (AIM: GENI), the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces that its interim results for the six months ended 30 June 2021 will be released on Thursday, 16 September 2021.

Analyst briefing

A briefing open to analysts will take place remotely via video conference call on Thursday, 16 September at 11.30 a.m. (BST). If you would like to register for this call, please contact Walbrook PR at GENinCode@walbrookpr.com .

Investor presentation

Chief Executive Officer, Matthew Walls, and Chief Financial Officer, Paul Foulger, will also provide a live presentation relating to GENinCode plc's interim results via the Investor Meet Company platform on 16 September 2021 at 16:00 p.m. (BST).

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 a.m. (BST) the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet GENinCode plc via:

https://www.investormeetcompany.com/genincode-plc/register-investor

Investors who already follow GENinCode plc on the Investor Meet Company platform will automatically be invited.

Contacts:

 
 GENinCode plc                                                          www.genincode.com 
 Matthew Walls, CEO                                                       Via Walbrook PR 
 Paul Foulger, CFO 
 
 Stifel Nicolaus Europe Limited (Nomad and                       Tel: +44 (0)20 7710 7600 
  Joint Broker) 
 Alex Price / Ben Maddison / Richard 
  Short 
 
 Cenkos Securities Plc (Joint Broker)                            Tel: +44 (0)20 7397 8900 
 Giles Balleny 
 Dale Bellis / Michael Johnson (Sales) 
 
 Walbrook PR Limited                      Tel: 020 7933 8780 or genincode @walbrookpr.com 
 Anna Dunphy / Paul McManus / Louis 
  Ashe-Jepson 
 
 

About GENinCode plc

GENinCode plc (AIM: GENI) is engaged in the risk assessment, prediction and prevention of cardiovascular disease ("CVD"). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company's products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess and predict the onset of CVD.

The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical and healthcare company. The technology and products acquired included Cardio inCode(R), Lipid inCode(R), Thrombo inCode(R) and Sudd inCode(R). The Directors believe that approximately EUR50 million has been invested in the research and development of these products since 2007. The Company has begun to commercialise these products in Europe and is now targeting the UK and US.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORLBMTTMTAMBTB

(END) Dow Jones Newswires

September 02, 2021 02:00 ET (06:00 GMT)

1 Year Genincode Chart

1 Year Genincode Chart

1 Month Genincode Chart

1 Month Genincode Chart
ADVFN Advertorial
Your Recent History
LSE
GENI
Genincode
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220522 00:21:07